Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events. 1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, 2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma. 3 , 4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. 5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.
Bibliographical noteFunding Information:
Funding Marina Serper receives funding from the National Institutes of Health (award 1K23DK1158907-03 ). Mary Thomson receives funding from the American Association for the Study of Liver Diseases Advanced/Transplant Hepatology Award. TARGET-NASH is a collaboration among academic and community investigators and the pharmaceutical industry. Target RWE is the sponsor of the TARGET-NASH study. We thank the study staff, nurses, health care providers, and participants at each study center for their contributions to this work.
Conflicts of interest These authors disclose the following: Marina Serper has received consulting fees from Gilead. Huy Trinh has served as a speaker and advisor for and owns stock in Gilead; and has received grant support from Gilead and Intercept. Michael Roden has served on the scientific advisory boards of Allergan, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Inventiva, Intercept Pharma, Novartis, Novo Nordisk, Servier Laboratories, Target Pharma Solutions, and Terra Firma; and has received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone, and Sanofi. Derek Gazis and Andrea R. Mospan are employees of Target RWE. Michael W. Fried is is Chief Medical Officer of Target RWE and is a stockholder in the company. K. Rajender Reddy has received research grants (paid to the University of Pennsylvania) for the HCV-TARGET, TARGET-HCC, and TARGET-NASH studies. Anna S. Lok has received research grants (to University of Michigan) from and served as advisor to Target RWE; and has served on the Data and Safety Monitoring Board for Novo Nordisk. The remaining authors disclose no conflicts.